Xencor, Inc. (XNCR) EPS Estimated At $-0.56

October 13, 2018 - By Clifton Ray

Investors sentiment increased to 1.82 in Q2 2018. Its up 0.12, from 1.7 in 2018Q1. It is positive, as 13 investors sold Xencor, Inc. shares while 26 reduced holdings. 26 funds opened positions while 45 raised stakes. 46.21 million shares or 5.48% more from 43.81 million shares in 2018Q1 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 2,546 shares or 0% of the stock. Employees Retirement Association Of Colorado owns 2,674 shares. First Advsrs Ltd Partnership has 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 64,248 shares. Eventide Asset Mgmt Limited Liability has invested 0.35% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). 12,300 are owned by Birchview Cap L P. Ubs Asset Management Americas has 0% invested in Xencor, Inc. (NASDAQ:XNCR). Bailard Incorporated holds 16,000 shares or 0.04% of its portfolio. Goldman Sachs Group Inc Inc reported 0% in Xencor, Inc. (NASDAQ:XNCR). Amalgamated Bancorporation holds 0.01% or 7,083 shares. Moreover, Td Asset Incorporated has 0.01% invested in Xencor, Inc. (NASDAQ:XNCR). Dekabank Deutsche Girozentrale holds 0% or 18,700 shares in its portfolio. California Pub Employees Retirement Systems has 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 49,491 shares. Alliancebernstein L P reported 65,700 shares. Oberweis Asset Mgmt Inc reported 8,100 shares. Panagora Asset Mngmt Inc has invested 0.02% in Xencor, Inc. (NASDAQ:XNCR).

Since June 13, 2018, it had 0 insider purchases, and 9 sales for $24.07 million activity. 138,300 Xencor, Inc. (NASDAQ:XNCR) shares with value of $5.49M were sold by STAFFORD JOHN S III. Dahiyat Bassil I sold $2.03 million worth of stock or 50,000 shares. Kuch John J sold $1.04 million worth of stock or 25,000 shares. $2.01 million worth of Xencor, Inc. (NASDAQ:XNCR) was sold by Baracchini Edgardo Jr on Thursday, August 9.

Analysts expect Xencor, Inc. (NASDAQ:XNCR) to report $-0.56 EPS on November, 6.They anticipate $0.23 EPS change or 69.70 % from last quarter’s $-0.33 EPS. After having $-0.46 EPS previously, Xencor, Inc.’s analysts see 21.74 % EPS growth. The stock increased 3.06% or $1.04 during the last trading session, reaching $35.04. About 254,658 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 101.72% since October 14, 2017 and is uptrending. It has outperformed by 86.10% the S&P500.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Among 4 analysts covering Xencor Inc (NASDAQ:XNCR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Xencor Inc had 5 analyst reports since April 26, 2018 according to SRatingsIntel. On Monday, September 10 the stock rating was reinitiated by BTIG Research with “Buy”. The company was maintained on Thursday, April 26 by Piper Jaffray. Cantor Fitzgerald maintained Xencor, Inc. (NASDAQ:XNCR) rating on Tuesday, May 8. Cantor Fitzgerald has “Buy” rating and $3700 target. The firm has “Buy” rating given on Wednesday, May 9 by Canaccord Genuity.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.96 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

More news for Xencor, Inc. (NASDAQ:XNCR) were recently published by: Seekingalpha.com, which released: “Key events next week – healthcare” on October 12, 2018. Seekingalpha.com‘s article titled: “Xencor announces mid-stage Lupus data on XmAb 5871; shares down 7% premarket” and published on October 05, 2018 is yet another important article.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.